Esperance Enrolls Patients for Studies of Membrane-Disrupting Agent

Drug discovery and development company Esperance Pharmaceuticals announced that it has begun enrollment and dosing of patients in a Phase I study of EP-100 in patients with advanced solid tumors.
Earth Times